International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

J. Le Heuzey | J. Healey | J. Camm | G. Boriani | J. Brachmann | L. Fauchier | B. Gersh | É. Marijon | W. Ageno | A. Camm | P. Beaudry | J. Wranicz | J. Iqbal | C. Indolfi | F. Sacher | L. Mattei | I. Diemberger | F. Gaita | J. Riancho | A. Leenhardt | L. Calò | K. Fox | A. Turpie | F. Pierron | M. Al-Murayeh | M. Ghani | M. Almansori | D. Poli | A. Falanga | D. Brieger | F. D. den Hartog | O. Tricot | V. Arrarte | M. Leschke | F. Pelliccia | U. Sechtem | A. Ross | F. Massari | Nadeau | J. Davy | A. Margonato | W. Jung | L. Frost | M. Gupta | L. Di Gennaro | K. Pieper | P. Vinson | D. Dutta | L. Ruocco | K. Appel | U. Rosenqvist | S. Appel | A. Kakkar | D. Imberti | C. Itty | M. Crisby | M. Bloch | T. Kameneva | M. Mamun | M. D. van de Wetering | J. Clua-Espuny | E. Gandjbakhch | R. Bhindi | C. Halperin | M. Mierzejewski | A. Cafolla | N. Zannad | R. Tan | A. Turpie | A. Bakhai | J. Neau | A. Mistri | R. Nijmeijer | L. Mos | D. Martín Raymondi | D. Gulba | J. Nieto | O. Amoudi | P. Miękus | G. Kayani | M. Gamba | A. Ardashev | A. Pinzani | J. Beyer-Westendorf | R. Quintavalla | S. Haas | A. Dompnier | J. Taieb | A. Milhem | R. García | S. Reinders | G. Cannavà | E. Crystal | J. Mansourati | A. Manoj | Helmy | D. Møller | L. M. Backes | S. Kirubakaran | V. Karetnikova | G. D. de Lima | R. Schilling | M. Tymiński | S. Bardari | S. Shaheen | J. A. de Figueiredo Neto | C. Anderson | K. Chatterjee | D. Broughton | Y. Shubik | D. Cross | W. Krzyżanowski | J. Korecki | R. Troquay | J. González Lama | F. Capasso | M. Tawfik | D. Wrońska | R. Lochan | R. Ghaleb | W. Comuth | L. Theunissen | T. Lässig | S. Virdone | Zia-ul-Sabah | A. Masswary | M. Elbadry | J. Fernández Portales | Y. Ghazi | B. Subbaraman | S. Kamal | V. Malquarti | J. Layland | C. Axthelm | P. Carroll | K. Lim | Ajay Kakkar | R. Howlett | N. Akhtar | J. Berlingieri | M. Seige | N. Badenco | G. Starmer | P. Napora | A. Drzewiecka | I. Aksoy | H. Domínguez | K. Leon | V. Sierra | N. Schön | J. Merke | T. Silvestrini | L. Bruun | S. Chanséaume | B. Singh | S. Zenin | V. Yakusevich | J. Berneau | J. Muller | E. Pokushalov | N. Lellouche | A. Quatre | B. Cederin | J. Kurian | J. Gemelli | A. Bakbak | A. Amlaiky | T. Schröder | J. Taggeselle | J. Cygler | H. Thomas | K. Eberhard | B. Hügl | I. Fares | J. Beyer‐Westendorf | A. Szyszka | S. Chopra | M. Krishnan | S. Baveja | R. Bergo | P. S. Thoppil | M. Andrade | I. Daoud | Dhillon | K. Saeed | Y. Khaykin | J. Torres Llergo | A. Kormann | J. Cooke | G. Drelich | S. Testa | Ekhlas | G. Kazamel | R. Lehman | C. Venkitachalam | C. E. B. de Lima | S. Boldueva | D. Bruce | B. Mikłaszewicz | E. Litwiejko-Pietryńczak | R. Bhargava | A. Costa-Vitali | R. J. van de Wal | K. Stania | J. L. Aziz | A. Almeida | M. S. Paiva | I. Dik | A. Catanchin | V. Rubino | G. Ladyjanskaia | N. Lyamina | Ajay K. A. John Jean-Yves Keith A. A. Jan Sylvia Alexan Kakkar Camm Le Heuzey Fox Beyer-Westendorf H | P. Hildebrandt | H. Christensen | J. Gauthier | C. Mielot | K. Chachoua | A. Salem | I. Lesto | J. Dshabrailov | C. Bauknecht | O. Scheuermann | A. Kopf | M. Schmiedl | K. Müller | G. Heinz | T. Schwarz | M. Patterson | E. D. Melker | F. Diks | J. Sumis | T. Kawka-Urbanek | J. Baška | D. Dronov | E. Isaeva | A. Lopukhov | D. Kuznetsov | I. Karpushina | D. Nikolin | A. Doletsky | A. Timofeeva | O. Miller | J. L. Blanco Coronado | C. González Juanatey | E. Otero | D. Alonso | J. A. V. De Prada Tiffe | F. J. García Seara | J. G. Gomez Doblas | J. Motero | G. Isasti Aizpurua | F. Marin | P. Alvarez Garcia | I. Torstensson | T. Kalm | J. Thulin | A. Hajimirsadeghi | S. Kumar | F. Ahmed | K. Barry | R. Stockwell | A. Broadley | J. Mccready | K. John | P. Pandya | Lim | P. Foley | A. Dixit | J. Taylor | A. Mortadda | M. Seleem | M. Aly | M. Hassan | M. Mostafa | M. Medhat | M. Taha | H. Al Din | A. Imam | M. El Hameed | B. M. Matto | M. Morsy | A. Bashir | Y. M. Al Hossni | B. Al Ghamdi | S. Mir | D. Dardir | A. A. Al Shehri | J. Rao | A. Aisheh | A. A. Albawab | A. Amanat | K. Esfehani | A. Bin Brek | B. Mittal | M. Krishna | S. Tabatabaei | S. Nasim | S. El Khider Nour | P. Barros | B. Garbelini | A. R. Alves Júnior | D. Salvadori Júnior | A. F. Freitas | C. E. Ornelas | J. Dantas | W. S. Barroso | F. R. dos Santos | J. A. de Lima Neto | P. R. Salvador Junior | A. López | J. C. P. Alva | F. G. Padilla-Padilla | A. Ruiz | K. Saunders | A. Begg | P. Davidson | J. Hickey | A. Lee | F. Padilla-Padilla | A. M. Imam | J. Beyer-Westendorf | Jean-Yves Le Heuzey | B. Singh | Á. A. Alves Junior | F. Marín | A. Lee | F. D. den Hartog

[1]  G. Lip,et al.  Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban , 2018, PloS one.

[2]  G. Lip,et al.  Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. , 2018, The American journal of medicine.

[3]  W. Shimizu,et al.  The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. , 2018, International journal of cardiology.

[4]  G. Lip,et al.  Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban , 2018, PloS one.

[5]  G. Lip,et al.  Two‐year follow‐up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long‐Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA‐AF) registry , 2018, American heart journal.

[6]  L. See,et al.  Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation , 2018, Journal of the American Heart Association.

[7]  G. Lip,et al.  Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program , 2018, Clinical cardiology.

[8]  T. Ikeda,et al.  Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS) , 2018, Journal of arrhythmia.

[9]  N. Choudhry,et al.  Patterns and predictors of physician adoption of new cardiovascular drugs. , 2017, Healthcare.

[10]  Emily C. O'Brien,et al.  Disease understanding in patients newly diagnosed with atrial fibrillation , 2017, Heart.

[11]  D. Fitzmaurice,et al.  Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) , 2018, European heart journal. Quality of care & clinical outcomes.

[12]  G. Fonarow,et al.  International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries , 2017, American heart journal.

[13]  G. Lip,et al.  Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry , 2017, Thrombosis and Haemostasis.

[14]  L. Huiart,et al.  Trends in the prescription of novel oral anticoagulants in UK primary care , 2017, British journal of clinical pharmacology.

[15]  G. Lip,et al.  Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry , 2017 .

[16]  J. Beyer-Westendorf,et al.  Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry , 2017, Journal of Thrombosis and Thrombolysis.

[17]  Jheel Pandya,et al.  NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation , 2017, Cureus.

[18]  G. Lip,et al.  The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. , 2017, Journal of the American College of Cardiology.

[19]  G. Lip,et al.  Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2017, British Medical Journal.

[20]  B. Gersh,et al.  Evolving quality standards for large-scale registries: the GARFIELD-AF experience , 2016, European heart journal. Quality of care & clinical outcomes.

[21]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. , 2016, Journal of the American College of Cardiology.

[22]  W. Shimizu,et al.  Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. , 2016, The Tohoku journal of experimental medicine.

[23]  A. Camm,et al.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation , 2016, Heart.

[24]  G. Lip,et al.  Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States , 2016, International journal of clinical practice.

[25]  G. Lip,et al.  Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  A. Camm,et al.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.

[27]  J. Beyer-Westendorf,et al.  Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[28]  J. Beyer-Westendorf,et al.  Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[29]  Ágnes Lublóy,et al.  Factors affecting the uptake of new medicines: a systematic literature review , 2014, BMC Health Services Research.

[30]  G. Fonarow,et al.  Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.

[31]  J. Beyer-Westendorf,et al.  Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. , 2014, European heart journal.

[32]  A. Camm,et al.  XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation , 2014, Vascular health and risk management.

[33]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[34]  G. Lip,et al.  Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. , 2014, American heart journal.

[35]  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[36]  R. Franken,et al.  Atrial fibrillation in the elderly , 2012, Journal of geriatric cardiology : JGC.

[37]  G. Lip,et al.  International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). , 2012, American heart journal.

[38]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[39]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[40]  JCSJointWorkingGroup.  Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[41]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[42]  M. Ezekowitz.  Atrial Fibrillation: The Epidemic of the New Millennium , 1999, Annals of Internal Medicine.